BridgeMD
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain ( TRIUMPH-7 )
EU CTIS ID: 2024-517431-43-00
What this study is testing
To demonstrate that retatrutide MTD is superior to placebo for change in average pain intensity and body weight.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Have had low back pain for at least the last 6 months
- Be overweight
- Have tried to lose weight by changing what they eat but it did not work
You likely can't join if
- Have a change in body weight greater than 11 pounds.
- Have diabetes
- Have prior history of low back surgery
The study team makes the final eligibility decision.
Where it's taking place
- United States
- Canada
- Argentina
- Mexico
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; Canada; Argentina; Mexico. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.